alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Federal Election Commission

# Date and Time:

Tuesday, October 23, 2007 at 10 A.M.

# PLACE:

999 E Street, NW., Washington, DC.

# STATUS:

This meeting will be closed to the public.

# ITEMS TO BE DISCUSSED:

Compliance matters pursuant to 2 U.S.C. 437g.

Audits conducted pursuant to 2 U.S.C. 437g, 438(b), and Title 26, U.S.C.

Matters concerning participation in civil actions or proceedings or arbitration.

Internal personnel rules and procedures or matters affecting a particular employee.

# PERSON TO CONTACT FOR INFORMATION:

Mr. Robert Biersack, Press Officer, Telephone: (202) 694-1220.

Mary W. Dove,

Secretary of the Commission.

[FR Doc. 07-5174  Filed 10-16-07; 3:28 pm]

BILLING CODE 6715-01-M
[Federal Register Volume 72, Number 203 (Monday, October 22, 2007)]
[Notices]
[Page 59541]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-5203]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Child Health and Human Development; Notice 
of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel, Environmental & Biological 
Variation and Language Growth.
    Date: October 11, 2007.
    Time: 1 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6100 Executive Boulevard, 
5B01, Rockville, MD 20852. (Telephone Conference Call)
    Contact Person: Marita R. Hopmann, PhD, Scientific Review 
Administrator, Division of Scientific Review, National Institute of 
Child Health and Human Development, 6100 Building, Room 5B01, 
Bethesda, MD 20892, (301) 435-6911, <a href="/cdn-cgi/l/email-protection#1f77706f727e7171725f727e76733171767731787069"><span class="__cf_email__" data-cfemail="cfa7a0bfa2aea1a1a28fa2aea6a3e1a1a6a7e1a8a0b9">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research; 93.209, 
Contraception and Infertility Loan Repayment Program, National 
Institutes of Health, HHS)

    Dated: October 12, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-5203 Filed 10-19-07; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<TABLE> <S> <C>

<ARTICLE> 7
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               SEP-30-1998
<DEBT-HELD-FOR-SALE>                           944,901
<DEBT-CARRYING-VALUE>                                0
<DEBT-MARKET-VALUE>                                  0
<EQUITIES>                                      69,697
<MORTGAGE>                                     216,300
<REAL-ESTATE>                                   42,159
<TOTAL-INVEST>                               1,385,374
<CASH>                                          22,591
<RECOVER-REINSURE>                             281,322
<DEFERRED-ACQUISITION>                         286,010
<TOTAL-ASSETS>                               2,376,898
<POLICY-LOSSES>                              1,275,870
<UNEARNED-PREMIUMS>                                  0
<POLICY-OTHER>                                  36,478
<POLICY-HOLDER-FUNDS>                           24,724
<NOTES-PAYABLE>                                224,250
<COMMON>                                        68,897
<PREFERRED-MANDATORY>                           25,247
<PREFERRED>                                     20,999
<OTHER-SE>                                     453,065
<TOTAL-LIABILITY-AND-EQUITY>                 2,376,898
<PREMIUMS>                                     219,297
<INVESTMENT-INCOME>                             93,834
<INVESTMENT-GAINS>                               5,575
<OTHER-INCOME>                                 124,421
<BENEFITS>                                     122,581
<UNDERWRITING-AMORTIZATION>                     31,282
<UNDERWRITING-OTHER>                           117,603
<INCOME-PRETAX>                                 53,636
<INCOME-TAX>                                    28,884
<INCOME-CONTINUING>                             24,752
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    24,752
<EPS-PRIMARY>                                     1.20
<EPS-DILUTED>                                     1.19
<RESERVE-OPEN>                                       0
<PROVISION-CURRENT>                                  0
<PROVISION-PRIOR>                                    0
<PAYMENTS-CURRENT>                                   0
<PAYMENTS-PRIOR>                                     0
<RESERVE-CLOSE>                                      0
<CUMULATIVE-DEFICIENCY>                              0
        

</TABLE>
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 1 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 2 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 3 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 4 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 5 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 6 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 7 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 8 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 9 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 10 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 11 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 12 of 13
Case 4:10-cv-00035-RH-WCS Document 1 Filed 02/01/10 Page 13 of 13
Case 1:07-cv-03408-DLC Document 8 Filed 06/19/2007 Page 1 of 2Case 1:07-cv-03408-DLC Document 8 Filed 06/19/2007 Page 2 of 2
Case 1:07-cv-03345-RJS Document 38-5 Filed 09/05/2008 Page 1 of 7
Case 1:07-cv-03345-RJS Document 38-5 Filed 09/05/2008 Page 2 of 7
Case 1:07-cv-03345-RJS Document 38-5 Filed 09/05/2008 Page 3 of 7
Case 1:07-cv-03345-RJS Document 38-5 Filed 09/05/2008 Page 4 of 7
Case 1:07-cv-03345-RJS Document 38-5 Filed 09/05/2008 Page 5 of 7
Case 1:07-cv-03345-RJS Document 38-5 Filed 09/05/2008 Page 6 of 7
Case 1:07-cv-03345-RJS Document 38-5 Filed 09/05/2008 Page 7 of 7
**EXHIBIT10.3**

 

**DEMAND PROMISSORY NOTE**

 

 
| $225,809.49 |   | Due:  June 15, 2004 |
|-------------|--------|--------------------------|

 

For value received, theundersigned, Lee Pharmaceuticals (the “Borrower”), hereby acknowledges itselfindebted to Henry L. Lee, Jr. (the “Lender”) and promises to pay on demand toor to the order of the Lender, at South El Monte, California, or as otherwisedirected in writing by the Lender, the principal sum of $225,809.49 withinterest thereon at the rate of 12% per annum, compounded monthly, based on a365-day year, actual day month.

 

The Lender may assign allof his right, title and interest in, to and under this demand promissorynote.  All payments required to be madehereunder shall be made by the Borrower without any right of set off or counterclaim.

 

The Demand PromissoryNote shall be governed by and interpreted in accordance with the laws of theState of California.  This note isunsecured.

 

 
| JUNE 15, 2004 |                                       | RONALD G. LEE      |   |
|---------------|--------------------------------------------|--------------------|--------|
|          | Lee Pharmaceuticals by  Ronald G. Lee      |
|          | President                                  |
|          |                                       |
|          |                                       |
| JUNE 15, 2004 |                                       | MICHAEL L. AGRESTI |   |
|          | Lee Pharmaceuticals by  Michael L. Agresti |
|          | Vice President -  Finance                  |

 

----
<TABLE> <S> <C>

         <S> <C>
<ARTICLE>     5
<S>                                                        <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END>                                           JUL-31-2000
<PERIOD-START>                                              AUG-01-1999
<PERIOD-END>                                                OCT-31-1999
<CASH>                                                           172397
<SECURITIES>                                                          0
<RECEIVABLES>                                                      2500
<ALLOWANCES>                                                          0
<INVENTORY>                                                           0
<CURRENT-ASSETS>                                                 174897
<PP&E>                                                          3154277
<DEPRECIATION>                                                    67212
<TOTAL-ASSETS>                                                  3647468
<CURRENT-LIABILITIES>                                             41565
<BONDS>                                                               0
<PREFERRED-MANDATORY>                                                 0
<PREFERRED>                                                           0
<COMMON>                                                        1879898
<OTHER-SE>                                                       842618
<TOTAL-LIABILITY-AND-EQUITY>                                    3647468
<SALES>                                                               0
<TOTAL-REVENUES>                                                  86276
<CGS>                                                                 0
<TOTAL-COSTS>                                                    148445
<OTHER-EXPENSES>                                                      0
<LOSS-PROVISION>                                                      0
<INTEREST-EXPENSE>                                                 4484
<INCOME-PRETAX>                                                  (54485)
<INCOME-TAX>                                                      21042
<INCOME-CONTINUING>                                              (33443)
<DISCONTINUED>                                                        0
<EXTRAORDINARY>                                                       0
<CHANGES>                                                             0
<NET-INCOME>                                                     (33443)
<EPS-BASIC>                                                     (4.20)
<EPS-DILUTED>                                                     (4.20)


</TABLE>
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 1 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 2 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 3 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 4 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 5 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 6 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 7 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 8 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 9 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 10 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 11 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 12 of 13
Case 1:09-cv-00257-MP -AK Document 137 Filed 08/17/10 Page 13 of 13
| 1. | The Report that this certification accompanies fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The information contained in the Report that this certification accompanies fairly presents, in all material respects, the financial condition and results of operations of Cytori Therapeutics, Inc. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                        | By:    | /s/ Marc H. Hedrick, MD                   |
|-----------------------------|--------|-------------------------------------------|
| Dated:  March 24, 2016 |   | Marc H. Hedrick, MD                       |
|                        |   | President & Chief Executive Officer   |
|                        |   |                                      |
|                        | By:    | /s/ Tiago M. Girão                   |
| Dated:  March 24, 2016 |   | Tiago M. Girão                       |
|                        |   | VP of Finance and Chief Financial Officer |
Exhibit 31.3

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

﻿

﻿

I, Necip Sayiner, certify that:

﻿

|  | 1.I have reviewed this amended annual report on Form 10-K/A of Intersil Corporation for the year ended December 30, 2016; |
|--|---------------------------------------------------------------------------------------------------------------------------|

﻿

|  | 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
|--|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

﻿

Dated: February 23, 2017

﻿

| ﻿ | /s/ Necip Sayiner                                    |
|----------|------------------------------------------------------|
| ﻿ | Necip Sayiner

President and Chief Executive Officer |

﻿

﻿

----
[Federal Register Volume 70, Number 25 (Tuesday, February 8, 2005)]
[Notices]
[Page 6715]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-2351]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel, Ancillary Studies to 
Obesity Related Clinical Trials.
    Date: March 22, 2005.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 
20852.
    Contact Person: D. G. Patel, PhD, Scientific Review 
Administrator, Review Branch, DEA, NIDDK, National Institutes of 
Health, Room 755, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, 
(301) 594-7682, <a href="/cdn-cgi/l/email-protection#ee9e8f9a8b828a89ae80878a8a85c0808786c0898198"><span class="__cf_email__" data-cfemail="83f3e2f7e6efe7e4c3edeae7e7e8adedeaebade4ecf5">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: February 2, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-2351 Filed 2-7-05; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 18-6400

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v.

COREY DEWAYNE KERR,

Defendant - Appellant.

Appeal from the United States District Court for the Middle District of North Carolina, at 

Greensboro. N. Carlton Tilley, Jr., Senior District Judge. (1:11-cr-00219-NCT-1; 1:15-

cv-00005-NCT-JLW)

Submitted: June 21, 2018 Decided: June 26, 2018

Before DIAZ and HARRIS, Circuit Judges, and SHEDD, Senior Circuit Judge.

Dismissed by unpublished per curiam opinion.

Corey Dewayne Kerr, Appellant Pro Se. 

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Corey Dewayne Kerr seeks to appeal the district court’s order accepting the 

recommendation of the magistrate judge and denying relief on Kerr’s 28 U.S.C. § 2255 

(2012) motion. The order is not appealable unless a circuit justice or judge issues a 

certificate of appealability. 28 U.S.C. § 2253(c)(1)(B) (2012). A certificate of 

appealability will not issue absent “a substantial showing of the denial of a constitutional 

right.” 28 U.S.C. § 2253(c)(2) (2012). When the district court denies relief on the merits, 

a prisoner satisfies this standard by demonstrating that reasonable jurists would find that 

the district court’s assessment of the constitutional claims is debatable or wrong. Slack v. 

McDaniel, 529 U.S. 473, 484 (2000); see Miller-El v. Cockrell, 537 U.S. 322, 336-38 

(2003). When the district court denies relief on procedural grounds, the prisoner must 

demonstrate both that the dispositive procedural ruling is debatable, and that the motion 

states a debatable claim of the denial of a constitutional right. Slack, 529 U.S. at 484-85. 

We have independently reviewed the record and conclude that Kerr has not made 

the requisite showing. Accordingly, we deny a certificate of appealability and dismiss the 

appeal. We dispense with oral argument because the facts and legal contentions are 

adequately presented in the materials before this court and argument would not aid the 

decisional process.

DISMISSED
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Child Health and Human Development Special Emphasis Panel, Pregnancy and HIV Prevention.                    

*Date:*                         October 29-30, 2007.                    

*Time:*                         8:30 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Renaissance Mayflower Hotel, 1127 Connecticut Avenue, NW., Washington, DC 20036.                    

*Contact Person:*                         Carla T. Walls, PhD, Scientific Review Administrator, Division of Scientific Review,  National Institutes of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, (301) 435-6898,                         *wallsc@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mother and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: September 27, 2007.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07-4926 Filed 10-3-07; 8:45 am]

BILLING CODE 4140-01-M